Abstract
Although the precise pathogenesis of coronavirus disease 2019 (COVID-19) currently remains unknown, its complex nature is gradually being revealed. COVID-19 is a disease caused by the SARS-CoV-2 virus and leads to respiratory dysfunction. Studies on hemostatic parameters have showed that COVID-19 significantly affects the disruption of the coagulation system and may contribute to coagulation and thrombotic events. A relevant cause of hemostasis disorders is inflammation and cytokine storms, which cause, for example, endothelial dysfunction in blood vessels. In order to prevent and treat states of hypercoagulability and thrombosis, the administration of anticoagulants, e.g., heparin, is recommended. The present mini-review describes the relationship between hemostasis and COVID-19, and discusses whether this relationship may cast light on the nature of COVID-19. The present short manuscript also examines the relationship between blood platelets and COVID-19. In addition, the paper explores the potential use of antiplatelet drugs in COVID-19 cases. The studies were identified by searching electronic databases, including PubMed and SCOPUS.
Highlights
Hemostasis is a set of mechanisms aimed at, on the one hand, ensuring the fluidity of blood in the blood vessels and, on the other hand, the rapid inhibition of bleeding when the vessel wall is interrupted
disseminated intravascular coagulation (DIC) is a serious disease associated with the overstimulation of the coagulation system, which leads to the formation of microvascular thrombosis, which is associated with an increased risk of bleeding with hyperfibrinolysis and even organ failure
Preliminary results indicate that patients affected by COVID-19 demonstrate various hemostasis dysfunctions, such as coagulation dysfunction, this being a major cause of death [4]
Summary
Hemostasis is a set of mechanisms aimed at, on the one hand, ensuring the fluidity of blood in the blood vessels (preventing excessive clotting) and, on the other hand, the rapid inhibition of bleeding when the vessel wall is interrupted. In many patients with COVID-19, hemostasis disorders have been observed, which increase the risk of developing DIC (disseminated intravascular coagulation) and coagulopathy [3]. The participation of blood platelets in the pathogenesis of COVID19 remains poorly understood, the influence of the mean size and reticulation, and the stages of platelet activation, such as aggregation. This short manuscript describes the role of blood platelets in COVID-19. It discusses the potential use of antiplatelet medication in treating COVID-19 based on a review of studies identified in electronic databases, including PubMed and SCOPUS.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
